Literature DB >> 30290439

STAT5 activity in pancreatic β-cells.

Louise T Dalgaard1, Nils Billestrup2, Jens H Nielsen3.   

Abstract

Signal transducer and activator of transcription (STAT)5A and -5B are latent transcription factors activated by cytokines and hormones of the cytokine family. In pancreatic insulin-secreting β-cells, STAT5A and -5B are activated primarily by prolactin and growth hormone stimulation and are important mediators of the potent stimulation of proliferation and insulin production caused by these hormones. STAT5A and -5B are both expressed in β-cells and control the expression of a number of mRNAs implicated in cell replication control, insulin biosynthesis and secretion. In addition to STAT5A and -5B being transcriptional activators, they may also repress gene transcription. By these means, STAT5 proteins increase the levels of anti-apoptotic transcripts in β-cells and repress expression of pro-apoptotic genes. This review focuses on the anti-apoptotic role of STAT5 signaling, providing a mechanism for β-cell resistance to pro-apoptotic cytokines, Type 1 diabetes mellitus and obesity-associated β-cell stress. It is clear from studies of STAT5 signaling in pancreatic β-cells that STAT5 is important for postnatal β-cell compensatory growth (as in pregnancy or obesity) and in the defense against β-cell stress factors.

Entities:  

Keywords:  STAT5; Type 1 diabetes mellitus; Type 2 diabetes mellitus; growth hormone; pancreatic β-cell; pregnancy; prolactin; signal transduction; transcription factor

Year:  2008        PMID: 30290439     DOI: 10.1586/17446651.3.4.423

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  1 in total

1.  Prolactin Receptor Signaling Regulates a Pregnancy-Specific Transcriptional Program in Mouse Islets.

Authors:  Mark E Pepin; Hayden H Bickerton; Maigen Bethea; Chad S Hunter; Adam R Wende; Ronadip R Banerjee
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.